acoramidis

Bayer pays $310M to buy into BridgeBio heart drug
BioPharma Dive
Mon, 03/4/24 - 11:52 am
BridgeBio
Bayer
acoramidis
Pfizer
Vyndamax
transthyretin amyloidosis cardiomyopathy
AstraZeneca's phase 3 heart disease trial hits, teeing up Pfizer showdown in Japan
Fierce Biotech
Fri, 02/2/24 - 11:53 am
AstraZeneca
Pfizer
acoramidis
Japan
clinical trials
cardiomyopathy
ATTR-CM
BridgeBio gears up for FDA review of acoramidis following Phase III results
Clinical Trials Arena
Thu, 01/11/24 - 11:07 am
BridgeBio
FDA
acoramidis
clinical trials
BridgeBio makes $250M in securities sale while planning acoramidis commercial launch
Fierce Biotech
Mon, 09/25/23 - 11:51 am
BridgeBio Pharma
acoramidis
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Yahoo/GlobeNewswire
Sun, 08/27/23 - 04:28 pm
Bridge Bio
clinical trials
acoramidis
ATTR
ATTR-CM
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Why BridgeBio Pharma Stock Is Plunging Today
Motley Fool
Thu, 06/15/23 - 06:56 pm
BridgeBio
clinical trials
acoramidis
ATTR-CM
BridgeBio says trial for acoramidis in transthyretin amyloidosis did not meet main goal
Seeking Alpha
Mon, 12/27/21 - 11:16 am
BridgeBio
acoramidis
clinical trials
transthyretin amyloidosis
Bridgebio sets its heart on besting Pfizer
EP Vantage
Fri, 12/3/21 - 10:31 am
BridgeBio
Pfizer
acoramidis
Vyndaqel
amyloidosis
transthyretin amyloid cardiomyopathy